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Tumor-Suppressor Genes: Cardinal Factors in
Inherited Predisposition to Human Cancers
by H. John Evans1 and Jane Prosser1
A predisposition to the development of certain specific and familial cancers is associated with the
inheritance of a single mutated gene. In the best-characterized cases, this primary mutation is a loss of
function mutationconsistentwithviabilitybutresultinginneoplasticchangeconsequenttotheacquisitionof
a second somatic mutation atthe same locus. Such genes are referredto as tumor-suppressor genes. Classical
examples are the Rb-i gene associated with the development of retinoblastoma and thep53 gene, which is
associated with awiderrangeofneoplasms, includingbreastcancer.Othertumor-suppressorgenes havebeen
isolated which are associated with Wilms' tumor, neurofibromatosis, and inherited and sporadic forms of
colorectal cancer. Some ofthese genes appear to act as negative regulators ofmitotic cycle genes, and others
may have differentproperties. The nature ofthese genes is discussed, as is the evidence forthe involvement of
tumor-suppressor genes in other inherited, and sporadic, forms of cancer. Some recent data on the Wilms'
tumorgene, WT1, andonthe involvementofthep53 gene inbreastcancerarepresented, andthe importance of
genomic imprinting in contributing to the excess of suppressor gene mutations in chromosomes ofpaternal
origin is considered.
Introduction
Cancers are genetic diseases that are a consequence of
alterations in the structure, expression, and hence func-
tion of usually more than one of a variety of genes.
Transformation to a neoplastic state can be viewed as an
untoward outcome of the competing forces of cellular
differentiation, hibernation (quiescent stem cells), or pro-
grammeddeath (apoptosis) onthe onehand, andprolifera-
tion on the other; the genes and genetic systems involved
incontrollingthese processes aretherefore obvious candi-
dates in the quest for genetic factors ofimportance. In a
normal proliferating tissue, the maintenance of home-
ostasis depends upon the retention of an appropriate
population ofstem cells with the propensity for prolifera-
tion and the production ofthe required number of differ-
entiated cells for that tissue. Such a system depends upon
abalancebetweencontrollingsignals specifyingprolifera-
tionandthoseinhibitingthe passage ofcellsthrough acell
cycle. These signals, and the genes thatspecifythem, may
beviewed aspositive ornegative,promoting orinhibiting a
programmedchainofevents. In asomewhatoversimplified
way, we consider those genes which, in an altered or
overexpressed form, actin apositive and dominant wayto
promote proliferation as oncogenes and those in which
mutational change,usually(butnotalways) expressed in a
homozygous or hemizygous state, results in a negation of
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their normal inhibitory action on proliferation as tumor-
suppressing genes.
Theevidencefordominantlyactingoncogenesstemmed
initially from studies on virallyinduced tumors in rodents
and chickens, and there are now at least 50 or so defined
oncogenes in the human genome. The normal functions of
these genes are to code for growth factors, growth factor
receptors, second messenger proteins, or transcription
factors as components that regulate normal cell growth
andproliferation. Intheiraltered, oroverexpressedforms,
they can, however, cooperate in inducing cell transforma-
tion in vitro or tumorigenesis in vivo. The importance of
oncogenes in the initiation and development of human
cancers is well established and has been reviewed exten-
sively (1,2); such genes are therefore referred to only
briefly here in the context of our discussion on tumor-
suppressorgenes.Theideathatothergenesinthegenome
act as tumor-suppressor genes stems from three kinds of
observation: on cell hybrids between tumorigenic and
nontumorigenic cells; on mutations, including constitu-
tional loss ofheterozygosity (LOH) at specific chromoso-
mal sites, in a variety of inherited predispositions to
cancer in childhood; and on acquired LOH at specific
chromosomal sites in specific sporadic tumors. The early
studies ofHarris and colleagues (3) were among the first
to clearlydemonstrate thatthe property oftumorigenesis
is lost in hybridomas between certain tumorigenic and
nontumorigenic cells but is regained in descendant segre-
gant cells that have lost specific chromosomes. This
approach ofintroducing genomes, chromosomes, or genes
from normal cells intotheirtumorigenic counterparts hasEVANS AND PROSSER
beenused extensively overthepast20years as ameans of
identifying, orconfirmingthenature of,tumor-suppressor
genes (4).
The mutations in oncogenes that convert them into
transforminggenes areoftenrelativelyspecificandinvari-
ably result in an altered, but functional, gene product.
Transformation may also follow as a consequence ofinap-
propriate expression, eitherintime orin quantity, and the
nature and dominance of many of the known changes
would in most cases be inconsistent with normal develop-
ment and viability of an early embryo/fetus. In contrast,
those suppressor genes that are revealed by loss offunc-
tionmightbe expected toyield awiderrange ofmutations
many ofwhich would be viable in the heterozygous state.
Hence in atwo-hitmodel oftumorigenesiswhichproposes
that both copies of a tumor-suppressor gene be func-
tionally inactivated for the development of a tumor, such
genes in their heterozygous state could result in the
inheritance of a predisposition to cancers. Most types of
human cancer exist in both sporadic and inherited forms.
Indeed, identification and characterization of the first
tumor-suppressor genefollowedfromstudies ontheinher-
itedchildhoodcancerofretinoblastoma. Itmaybeinstruc-
tive, therefore, to reviewbriefly some ofthe developments
in our understanding of the role of tumor-suppressor
genes in the better understood inherited cancer pre-
dispositions, inwhich someoftherelevantgeneshavebeen
cloned and information is available on their function.
Retinoblastoma
Retinoblastoma, a tumor of the retina which affects
some 1 in 5000 children, occurs in two forms: 30-40% of
caseshavebilateral andusuallymultifocaltumorsthatare
evident at an earlier age than the commoner unilateral
cancers. The earlier onset of multiple tumors is often
associatedwith afamilial history, and in 1971 Knudson (5)
proposed that these tumors arise from two sequential
mutations. In the familial form the firstmutation is inher-
ited and therefore constitutional and the second mutation
is acquired and somatic; in the sporadic form, both muta-
tionsaresomatic.Aconstitutionaldeletionofbandq14.1 on
chromosome 13wasreportedin anumberoffamilial cases
(6),andsimilar,butsomaticandtumor-specific, deletionsin
a number of sporadic tumors (7). The alteration was
therefore considered tobe aloss, orloss-of-function muta-
tion at 13q14. Cavenee et al. (8), using a series of DNA
markers for13q, showed thatthe chromosome 13 fromthe
nonaffectedparentwaslostinfamilial tumorsandthatthe
LOH thus acted to uncover an inherited constitutional
mutation. Retinoblastoma appeared therefore to be a con-
sequence of mutations affecting both alleles of a single
gene (rbl) so that although the predisposition to this
condition isinherited as an apparentautosomal dominant,
at the cellular level the expression ofneoplasia is a conse-
quence ofrecessive changes.
The studies of Friend et al. (9) and Lee et al. (10)
identified the gene responsible for retinoblastoma and
showedthatitcodesfora928aminoacidprotein,p105-Rb.
A number of studies have since reported a range of
different mutations, including large and small deletions,
and point mutations that alter amino acid sequence or
splicingproducts,whichyield anabsentorinactiveprotein
in tumor cells and cell lines (11-13). The Rb protein is a
nuclearprotein presentin all types ofcells and is found in
phosphorylated and nonphosphorylated forms (14). The
state ofphosphorylation alters duringthe cell cycle, being
maximal at the beginning of the DNA synthesis S phase
and minimal after mitosis and entry into Gi (15,16). The
stimulation of quiescent T lymphocytes to proceed
through amitotic cycle results in phosphorylation ofp105-
Rb (17) and the loss ofproliferative capacity in senescent
human fibroblast cultures exposed to growth factors is
associated with the absence of phosphorylation. Overall
the data would suggest that phosphorylation of Rb is
necessaryfor cell cycling, and inparticularforthe transi-
tionfromtheG1 toSphase,andthatinitshypophosphory-
lated form the normal protein is associated with the
suppression of mitosis. This suppression can be negated
notonlybyphosphorylation, but also byinactivation ofthe
Rb protein following its association with the tumorigenic
proteins of a variety of DNA tumor viruses, i.e., ade-
novirus ElA, SV40 and polyomavirus large T, and human
papillomavirus E7 (18-21). Some mutant Rb proteins can-
notundergophosphorylation anddonotcomplexwithviral
tumorigenic proteins (12). In vivo the Rb protein com-
plexes with a number of cellular proteins which interact
with the same region that is important in binding DNA
viral tumor proteins and the region frequently found
mutated in tumors in which Rb is implicated (22). Recent
studies have identified a specific binding of Rb proteins
with the transcription factor E2F (23-25), a factorwhich
alsobindstothepromoters ofseveral cellularproliferation
related genes, including the cell cycling protein cyclin A
(26). The expression of such genes could therefore be
regulated through Rb binding/sequestration of essential
transcription factors.
The evidence that the Rbl gene acts as a tumor-
suppressor gene was strongly supported by the demon-
stration that the introduction of normal Rb into reti-
noblastoma or osteosarcoma cell lines devoid of normal
p105-Rb suppresses the growth and tumorigenicity ofthe
cells (27). Rb mutations are indeed found sporadically in a
variety of human tumors, and suppression of tumori-
genicityhas alsobeenreportedfollowingtheintroduction
ofanormalRb geneinto ahuman prostate cancercellline
(28) and into a bladder carcinoma cell line (29). Although,
to date, there has been no report of a transgenic mouse
containing amutated Rb gene, Windle et al. (30) reported
the occurrence ofretinal tumors in transgenic animals in
whichtheSV40Tantigenwasspecificallyexpressedinthe
retina.TheevidenceindicatesthattheTantigenproteinin
theretinoblastoma cellsbound top105-Rb, supportingthe
role of the inactivated Rb protein in retinal oncogenesis.
Althoughretinoblastomaistheparadigmaticexampleof
the consequences ofanullmutation atatumor-suppressor
locus, it remains unclear whether additional mutational
steps are necessary for the full emergence of tumors. It
has been remarked that nonmalignant retinomas can
occur in Rb carriers (31), but there is no information on
26TUMOR-SUPPRESSOR GENES IN INHERITED CANCERS
their frequency or on their genetic constitution. There is
considerable evidence that malignant retinoblastomas
may contain a range of consistent chromosomal abnor-
malities, including abnormalities oflq and 17p, in addition
to the mutation at 13q14 (32,33).
Wilms' Tumor
Wilms' tumor, a nephroblastoma with an incidence of
around 1 in10,000, is oneofthemostcommon solid tumors
ofchildhood. Most cases are sporadic andunilateral, buta
smallproportion (-8%) arebilateral, and afurther1% are
clearly familial. From a study of the age at onset of
unilateral and bilateral cases, Knudson and Strong (34)
suggested that the etiology of Wilms' tumor parallelled
that ofretinoblastoma and that the occurrence ofWilms'
tumor involved two mutational events at a single gene
locus.
Cytogenetic studies of sporadic tumors and of blood
lymphocytes and tumors in inherited forms ofthe disease
initially implicated a gene at chromosomal band llpi3 in
theetiologyofsome,butnotall, casesofWilms'tumor(35).
This suggestionwassupportedbytheresults ofmolecular
genetic studies using relevant DNAmarkers (36-38), and
the datawere consistentwiththe notionthat amutation of
one lipl3 allele and subsequent mutation or loss of the
homologous allele were necessary, butperhaps not suffici-
ent, for tumorigenesis. Recent results of chromosome
walking and jumping to detect CpG island sites in this
region have led to the independent isolation of cDNA
clones that encode a transcription factor with four zinc
fingers and aproline-richdomain; thereis strongevidence
thatitis acandidateWTgene(39,40).Workinourownunit
(41) ontheexpressionofthisgeneintheearlyhumanfetus
shows that it is expressed in fetal kidney, gonads, and
spleen, asmighthavebeenexpectedifthegenewasindeed
the WT1 Wilms' tumorgene. Conclusive evidencethatthis
is so was recently presented by Huff et al. (42), who
detected a constitutional heterozygosityfor a small intra-
genic deletion in WT1 in a patient with bilateral Wilms'
tumor and then indicated thathomozygosityforthis dele-
tion was present in both tumors. Loss of constitutional
heterozygosity for linked DNA markers showed that the
homozygosityinthebilateral tumors hadbeenengineered
by two different genetic events. Work in our unit (43) has
resultedinidentification oftwodifferentstructurallycriti-
cal zinc-finger point mutations in two Wilms' tumor
patients; inthepatientwithbilateral tumors, themutation
was constitutional and present in a hemizygous state in
one tumor. These data fully support the notion that the
WT1 gene is a tumor-suppressor gene.
Since this gene codes for a transcription factor, the
identification of target sequences to which it binds is
important. Rauscher et al. (44) have expressed the zinc-
finger domains of the WT1 gene in Escherichia coli and
used this protein as an affinity matrix for the isolation of
DNA target sequences. A sequence was identified that
turns out to be closely similar to a binding sequence
recognized by the product of the early growth response
gene-1, EGR-1, a zinc-finger protein that is induced by
mitogenic stimuli. A deletion in the third zinc finger of
the WT1 protein, a mutation that occurs naturally in
Wilms' tumor, was shown to reduce the binding activity
severely. The possibility exists that the normal WT1 pro-
tein may suppress the binding of proteins coded for by
the EGR-1 gene family, including genes likefos andjun
which respond to mitotic stimuli and regulate gene
transcription.
Although the two-hit tumor-suppressor model would
appear to be applicable for certain cases ofWilms' tumor
thepictureis notas simple as that seeninretinoblastoma.
Studies of two large families with Wilms' tumor have
shownthatthepredispositionis notlinkedto llp,implying
the importance of a mutation elsewhere in the genome
(45,46). Moreover, there is evidence for a second WTlocus
atiipl5 (47,48). Wilms' tumor is observed in patients with
the Beckwith-Weidemann syndrome and the gene forthis
syndrome is tightly linked to the insulin and insulinlike
growth factor-2 genes at lipi5 (49), and there is evidence
forimprinting atthe Igf2locus (seebelow).Atthepresent
time, data on alterations to WT1 genes are insufficient to
determine if they provide, in addition to classic tumor-
suppressor activity, a dominant/negative heterozygous
gene effect (cfp53) or, indeed, whether additional muta-
tions elsewhere in the genome are necessary.
Von Recklinghausen's
Neurofibromatosis
Von Recklinghausen's neurofibromatosis is a common
autosomal dominant disorder involving tissues derived
from the neural crest, and in particular the peripheral
nervous system, where it is associated with the develop-
ment of caf6-au-lait spots and benign neurofibromas in
over 90% of cases. The condition has a prevalence of
around 0.24.3 per 1000 individuals, and among its more
serious complications are the occasional development of
neurofibrosarcomas and optic gliomas. All cases result
fromtheinheritance ofamutantallele; since the mutation
rateofthisratherlargegene(NF-1)ishigh,approximately
1 x 10-4(50,51),then40-50%ofallcasesmustinvolvenew
mutations.
TheNF-1 genewasmapped, bylinkage analysis, to 17q
(52,53) and a candidate gene isolated from Von Reck-
linghausen's neurofibromatosis patients with constitu-
tional translocations affecting 17qii.2. This gene had
undergone a variety of different mutations in various
patients, implying that its loss offunction was a causative
factorinthesyndrome(54-56).Thegeneislarge,encoding
a 13-kb transcript and a protein of at least 2485 amino
acids; it is expressed in most, if not all, tissues and is
transcribed inhuman/rodent hybrids containing anormal
chromosome 17 but not in hybrids containing balanced
translocations from Von Recklinghausen's neurofibro-
matosis patients (56). The findings are therefore consis-
tentwiththeideathatthegeneactsasatumor-suppressor
gene, but it is not knownwhether second-hit mutations in
the normal copy of NF-1 are necessary for the develop-
ment ofthe neurofibrosarcomas, orwhether mutations at
other sites may be required.
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The mode of action of the NF-1 gene in its tumor-
suppressingrole isunclear, butthereis abundant evidence
that it plays a role in signal transduction pathways. A
series ofstudies (57-60) have shown thatthegene encodes
a cytoplasmic protein with a large region ofsimilar amino
acid sequence and functional homology to mammalian
GAP and to the IRAl and IRA2 gene products of Sac-
charomyces cerevisiae, which are known to inhibit yeast
ras. The NF-1 protein has been shown to interact with
mammalian p2lras, and indeed a segment ofhumanNF-1
cDNAcan inhibit the action ofbothwild-type and mutant
H-ras genes inyeast.
Familial and Sporadic Colorectal
Cancers
Theclassicsyndromeoffamilialcolorectal canceristhat
associated with dominant autosomally inherited familial
adenomatous polyposis (FAP), although there are other
nonpolyposis familial forms. FAP has a prevalence of
around 1 in10,000,whereasvariouslinesofevidencewould
suggest that other major genes may be responsible for a
significant proportion of colorectal cancers (61,62), and
familial studies showa3-foldincreasedriskinfirst-degree
relatives ofcolorectal cancer probands.
FAP is characterized by the development of hundreds,
or carpets of thousands, of colorectal adenomas, some of
which develop into frank carcinomas, and is transmitted
byagene (APC)mappingtothe q21regionofchromosome
5 (63-66). Adenomas in FAP patients show no loss ofthe
APCregion in theirmildly ormoderately dysplastic form,
butthosethatdevelopintocarcinomas appeartobeassoci-
ated with a deletion of the APC region in the normal
chromosome transmitted fromtheunaffected parent (67).
These findings suggest that the APC gene acts as a cell
recessive tumor-suppressor gene, a conclusion reinforced
by the demonstrations that transfected chromosomal
fragments that include the 5q21 region reverse the neo-
plastic phenotype of cultured rodent fibroblasts (68) and
that the introduction of a normal chromosome 5 into
human colorectal epithelial cells completely abrogates
their neoplasticity (69).
The development of colorectal carcinomas involves a
number of genetic changes, and, although APC loss/in-
activation maybe anecessaryevent, itmaynotbe entirely
sufficient for the development of overt neoplasticity.
Insight into other important mutational events has
stemmed from a variety of studies on sporadic colorectal
tumors. Of special interest are the observations of a
number of authors who report heterozygous loss of the
APC region in up to more than 50% of sporadic tumors
studied (70-72). Vogelstein and colleagues in particular
have demonstrated a high frequency ofheterozygous loss
and ofmutationwithin oneknowntumor-suppressor gene,
p53 on 17pl3.1 (73), and one probable tumor-suppressor
gene,DCCon18q (71). AcandidateAPCgene hasrecently
been isolated which is expressed in normal human and
rodent colorectal mucosa and a variety of other tissues
(74). The gene, located intheAPCregion, was observed to
be mutated in three colorectal carcinomas and is referred
to as the MCC gene (mutated in colon cancer). MCC
encodes an 829-amino-acid protein with a short region of
similarity to a G protein (cf NF-1); in the absence of
confirmation ofaconstitutional mutation intheMCCgene
in FAP patients, however, the question of whether the
MCC gene is indeed theAPC gene is still open.
TheDCCgene on chromosome 18q, a region that shows
heterozygous loss in more than 80% of colorectal car-
cinomas, was identified by Fearon et al. (75) and shown to
be expressed in most normal tissues but with a very
greatly reduced or absent expression in colorectal car-
cinomas. Mutations were detected in the gene in 12 of 94
carcinomas, andthepredicted amino acid sequence shown
to be closely similar to neural cell adhesion molecules and
other related cell surface glycoproteins.
The p53 gene on chromosome 17p is perhaps the most
studiedoftheknowntumor-suppressorgenesandisimpli-
cated not only in colorectal tumors but in a wide range of
other cancers (Table 1). The p53 protein is a 393-amino-
acid nuclear phosphoprotein which is expressed at very
low levels and with a short half-life in the majority of
normal mammalian cells (90). Itwas originally discovered
by coprecipitation with the transformingprotein, large T,
in SV40-infected cells (91) and later showntoform specific
complexes with the transforming proteins of other onco-
genic DNA viruses: E1B of adenovirus (92) and E6 of
HPV-16 and -18 (18,93). The abundance and state ofphos-
phorylation of p53 is cell cycle-dependent, being minimal
immediately following mitosis and increasing markedlyin
cells in the S and G2 phases (94). The protein acts as a
substrateforcdc2, apredominantlynuclearproteinkinase
that regulates the commitment of cells to undergo DNA
synthesis andwhich,in adephosphorylated form,triggers
cells to enter mitosis (95,96). These findings parallel re-
markablycloselythoseobservedwiththe Rbprotein, sug-
gesting a functional connection between p53 and Rb-105,
with the implication that both are involved in a common,
negatively regulating pathway in the proliferative cycle.
The functional similarity between p53 and Rb is further
reinforcedbythefindinginherpesvirus-infectedcellsthat
these proteins, together with other host replication pro-
teins, colocate at nuclear sites ofviral replication (97).
Initially, p53 was considered to be an oncoprotein, but
cDNA clones of p53 that had transforming properties
werelatershowntobemutant(98-100).Wild-typep53,but
not mutant forms, suppress the transforming properties
ofother oncogenes as well as the growth oftransformed
cells in culture (101). The tumor-suppressing role of p53
hasbeensupportedbytworecentstudies: first,byChenet
al. (102),whoshowedthattheintroductionofwild-typep53
genes into human osteosarcoma cells lacking endogenous
p53 completely abrogated the neoplasticity of the cells,
whereas the introduction of mutant p53 conferred a lim-
ited growth advantage; second by Baker et al. (103), who
showed that transfection of the wild-type p53 gene in
vitro resulted in a suppression of growth of colorectal
carcinoma but not adenoma cells. We should notlose sight
ofthe factthat none ofthe different mutantp53s assayed,
by transformation in vitro possesses the suppressing
activity ofthe normal gene (104-106).
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Timor site
Bladder
Brain
Breast
Colorectum
Liver cells
Table 1. Loss ofheterozygosity (LOH) at 17p andp53 mutations in various human tumors.
No. oftumors No. with LOH No. with p53
or cell linesa 17p (%) mutation (%)
18 17 (94) 11 (61)
4 4 (100) 2 (50)
60 33 (55) 15 (25)b
all
32c
52
,Oa
26+4a
20+8a
16
10
Lung 30a
40
Esophagus 14+4a
Ovary 16
aCell lines.
bMinimum number; estimatedfrequency, > 40%.
cSelected for LOH 17p.
32a
27
0
28
3 (60)
11 (100)
11 (29)
2 (13)
6 (60)
5 (17)
24 (86)
8 (50)
5 (50)
17 (57)
28 (70)
7 (39)
11 (69) 11 (91)
A study ofp53 in 58 colorectal tumors (83) showed that
most tumors ("90%) with a loss of one 17p had a p53
mutation on the remaining allele, but such mutations were
lessfrequent(30%)intumorscontainingbothcopiesof17p
and were relatively rare in adenomas. This pattern indi-
cates that the mutations and allelic losses become evident
at around the time oftransition frombenign to malignant
growth. The data also imply that the presence ofa single
mutant p53 allele may exert a dominant-negative effect
perhaps by binding to the wild-type protein and creating
an inactive oligomeric complex; this implication is sup-
ported by a number of studies (e.g., 104,107). It is worth
notingthatifthetumorigenic effects ofp53 are dependent
on knocking out gene activity, few gross deletions and
rearrangements havebeen observed. Muchmorefrequent
are point mutations in conserved regions, resulting in
alterations in amino acid sequence, which appear to pro-
mote proliferation and confer some selective advantage to
the tumor cells (100).
Familial and Sporadic Breast and
Ovarian Cancers
Familial forms of breast cancer have been recognized
for well over a century, and a woman's risk ofdeveloping
thedisease overagivenperiodisknowntobeincreasedby
upto3-foldifafirst-degreerelativehas hadbreastcancer
and by 5- to 10-fold if that relative had bilateral disease.
Various studies point to the importance of inherited fac-
tors, and in some cases the evidence would imply the
presence of an autosomal dominantly inherited suscep-
tibility allele (108). A number of groups have used poly-
morphic DNAmarkersinlinkage studies tolocalize apre-
disposing gene, and our own studies produced suggestive
evidence oflinkage in families with early, premenopausal
and usually bilateral, cancer to a region on chromosome
17p. None of these studies, however, including our own,
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yielded conclusive evidence probably because ofthe hetero-
geneity of the disease. Convincing evidence was recently
published byHall etal. (109),who obtained alogofthe odds
score of +5.98 forlinkage ofbreast cancer susceptibility to
the marker D17S74 in early-onset families and negative
scores inlate-onsetfamilies. We confirmed these findings in
some,butnotall (108), ofcancerfamilieswestudied sothat
a predisposing gene is located in chromosome 17q21 in
some families. Although there are various possible candi-
date geneswithinthatchromosomalregion,theparticular
susceptibility gene has not been identified.
Studies ofsomatic chromosomal changes in breast can-
cer tissues, and particularly those revealing consistent
LOH, have identified a number ofsites ofpossible tumor-
suppressor genes. Our early studies (110) showed that
more than 60% ofsporadicbreast cancersfrom aconsecu-
tiveseriesofpatientshadLOHforaregionofchromosome
17p; these results have been extended by ourselves (111)
and confirmed byothers (112,113). We further showed that
in 50% of the tumors there was overexpression of p53
mRNA and that this was correlated with LOH of 17p.
Overexpression ofp53 is associated with mutant forms of
the gene which result in a more stable gene product
(99,100). Detailed genomic DNA sequence analysis of
exons 5-9 (78, unpublished data)-which include most of
the conserved regions in which the majority ofp53 muta-
tions are found in other cancers-revealed thatp53 muta-
tionswerepresentin atleast25%(uptoanestimated40%)
ofthe 60 breast tumors studied. The studyofVarley et al.
(113) extended these findings: LOH at 17pl3 and/or
expression of mutant p53 was seen in 86% of 74 breast
cancers,underliningthefactthatalterationsinvolvingp53,
either by loss ofone allele and/orintragenic mutation, are
byfarthemostcommon geneticchangeinprimaryhuman
breast tumors.
Our suggestive linkage data on early familial breast
cancer andmarkers on17p (logofthe odds score of +2.0),
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andthefindingofahighfrequencyofmutations inthep53
gene at 17pl3.1 in sporadic breast cancers, led us to study
the genein normal blood cell DNAfrom individuals infive
families with breast cancer. No constitutional mutation of
p53was found (114). Recently, however, Malkin et al. (115)
and Srivastava et al. (116) described the presence of
constitutional p53 mutations in family members with Li-
Fraumeni syndrome. This syndrome is a rare autosomal,
dominantly inherited condition that is characterized by a
diverse range ofneoplasms, including breast cancers and
soft-tissue sarcomas, which develop relatively earlyin life.
The reported studies on DNA from normal skin fibro-
blasts orlymphocytes from affected andunaffectedmem-
bers of six different families describe the presence of a
constitutional point mutation (a base substitution) in the
p53 gene at codon 248 in three families, at245 in two, and
at258 in one.Alinkage studyon one familyconfirmed the
cosegregation ofthemutated chromosome withthe occur-
renceofneoplasms.Themostfrequentneoplasmobserved
was breast cancer (60 of a total of231 primary cancers),
whichwasabouttwice asfrequentassoft-tissue sarcomas
or brain tumors. All individuals appeared to have a single
wild-type p53 allele, and were therefore constitutional
heterozygotes for the mutation, and at least one parent
and two grandparents carried a p53 constitutional muta-
tion but had not developed cancer. These findings are
rather dramatic, but it should be noted that we have
observednomutationinoneLi-Fraumenifamilystudiedin
ourlaboratoryandthatasyetunpublisheddatafromother
laboratories describe such families both with and without
p53 mutations. The finding that individuals who are het-
erozygousforaconstitutionalmutationintheevolutionary
conserved region III ofthe p53 gene (117) are viable and
prone to the development ofavarietyofearly cancers is a
signal discovery, and the fact that some gene carriers do
not appear to manifest neoplastic disease begs the ques-
tion ofhowfrequentthis kind ofmutation isinthegeneral
population, and whether it is associated with inherited
cancer predisposition in non-Li-Fraumeni families.
Answers to these questions should be forthcoming
shortly, but meanwhile it is relevant to note that the
introduction ofconstructs ofmutated p53 genes into nor-
mal mouse embryos results in the development of neo-
plasms in some 20% of the resultant transgenic animals
(118). Although the transgenes were widely expressed
most of the tumors seen were lung adenomas, osteosar-
comas, and lymphomas, and the average age ofincidence
was11months. Thislonglatentperiodandtheabsenceofa
correlation between levels oftissue expression ofp53 and
the occurrence oftumors, imply that deregulation ofp53
alone is insufficient for tumor formation and that other
genetic, and perhaps tissue-specific epigenetic, changes
may be involved.
Familial breast cancer is often associated with familial
ovariancancer,and anumberofreportsindicate apossible
autosomal dominant mode ofinheritance of ovarian can-
cer. Following the report of Hall et al. (109) showing
linkage ofearly breast cancer cases in some families to a
regionon17q,Narodetal. (119)confirmedthisfindingand,
further, showed linkage between familial ovarian cancer
andthesamechromosomeregion,i.e.,17q12-23. Inparallel
with our studies on breast tumors, we have noted the
involvement of 17p in sporadic ovarian tumors; 13 of 16
advanced ovarian serous adenomas showed LOH for 17p,
and 11 ofthese tumors had a p53 mutation (89). In these
tumors LOH at 17p, detected bymarkers closelylinked to
p53, correlates closelywiththepresence ofap53mutation
in the remaining homolog.
Lossandmutationatthep53locusareclearlyimportant
features ofboth breast and ovarian cancers, but it should
be noted that there is some evidence in breast cancer for
the involvement of a second locus on 17p some 20 Mb
telomeric to p53 (81,120). Moreover, studies of sporadic
breasttumors haveuncoveredhighfrequencies ofLOH at
otherchromosomal sites, e.g. lp, lq,llp, 18q (121-123); and
loss of the Rb gene has also been reported in cases of
ductal breast cancer (14,124). The genes that may be
involved at these other sites have not been identified, but
tumor-suppressor genes other than those on 17p and 17q
may be important in breast cancer.
Other Inherited Cancer
Predispositions and Suppressor
Genes in Other Sporadic Cancers
Inadditiontothegenesinvolvedintheinherited cancer
predispositions and in sporadic cancers already referred
to, loci involved in other inherited cancers have been
assigned to specific chromosomes (Table 2). Although
these cancer-associated syndromes appeartobeinherited
as dominant autosomal conditions, the genes involved
might represent classical recessive tumor-suppressor
genes; but none has as yet been characterized. It is
unlikely to be merely coincidental that there is a chromo-
some 3 locus involved in the inherited von Hippel-Lindau
syndrome with its associated renal carcinomas, a similar
locus involved in a translocation of chromosome 3 that
segregateswithrenal cancerin onelargefamily(133), and
aLOHforthischromosomeregion describedbyKovacs et
al. (134) in 18 outof21 sporadicrenalcancers.Aconsistent
loss of 3p has also been noted in sporadic lung cancers
(135,136). A candidate tumor-suppressor gene (a receptor
protein-tyrosine phosphatase) at the 3p2l region has
indeed recently been isolated (137). In a number of renal
carcinoma cell lines and lung tumor samples, one allele of
thisgenewaslost,butthereisnoconclusiveevidenceofits
tumor-suppressing role in these cancers. Similarly, the
consistentinvolvementofchromosome22insporadicmen-
ingiomas (138) and the assignment of the gene for neu-
rofibromatosis type 2 associated with acoustic neuromas
to this chromosome should also be noted.
None of the conditions listed in Table 2 appears to be
associated with inherited defects in the repair of muta-
tional damage, but genes involved in one form of xero-
derma pigmentosum, Cockayne's syndrome (139), and
Bloom'ssyndrome(140)-threerecessiveautosomalcondi-
tions involving defective DNArepair-have recently been
identified. The gene defects in these three, and in other
putative DNA repair deficiencies, are presumably associ-
ated with inherited cancer predisposition by virtue of
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Table 2. Examples ofdominantly inherited cancer predispositions in which the mutated gene has not yet been identified.
LOH of
assigned
Chromosome chromosome
Syndrome lTmor assignment in tumors References
Multiple endocrine Pituitary adenomas/pancreas llq (centric) + Larson et al. (125)
neoplasia type 1
Multiple endocrine Medullary carcinoma ofthyroid 10 - Mathew et al. (126)
neoplasia type 2 Landsvater et al. (127)
Nelkin et al. (128)
Neurofibromatosis Acoustic bilateral neuromas 22 + Seizinger et al. (129),
type 2 Rouleau et al. (130)
von Hippel Lindau Renal-cell carcinoma, CNS, 3p + Seizinger et al. (131)
hemangioma, pancreas
Dysplastic nevus Melanoma ? ? Bergman et al. (132)
familial melanoma
LOH, loss ofheterozygosity.
inherited genomic instability and heightened mutation the observed preponderance ofmutation in the paternally
sensitivity. These genes may not be tumor-suppressor derived chromosome, and the consequent loss ofthe ma-
genes in the classical sense. ternal allele,withmuch ofthediscussion centeringuponthe
importance ofthe phenomenon of"genomic imprinting."
Genomic Imprinting and Patterns of "Genomic imprinting" is the term used to refer to the
Inheritance and Expression of differential expression (transcriptional inactivation) of
Mutated Suppressor Genes wholehaploidchromosomesetsinsomeinsects(150)orof segments of autosomes in mice (151,152), which is depen-
Itis evidentfrom studies on tumor-suppressor genes in dent upon the sex of the parent from which they are
various inherited cancer predispositions that a principal inherited. Studies in the mice suggest that such parental
mechanismintumorigenesisistheunmaskingofaninitial imprinting, which suppresses the expression ofsegments
(inherited) mutation (and in some cases its later duplica- ofthe genome, is a consequence ofmethylation (153). The
tion via disomy) by a subsequentmutation that eliminates methylation patterniserasedinprimordialgermcellsand
thewild-type allele. This elimination mayinvolvewhole or then reintroduced, in a modified form, in later germ-cell
partial chromosomal loss (8,72). Such unmasking can be stages or in early embryogenesis, the introduced pattern
recognized by loss of heterozygote status in appropriate being established by the parental sex of the germ cells
cases, and the parental origin of the original mutated (154). The first clear evidence that the phenomenon of
chromosome canbedetermined. Asimilaranalysismaybe genomic imprinting occurs in humans followed from the
undertaken in nonfamilial cases inwhich a newgerm-line discoverythatchildrenwithPrader-Willisyndromehave a
mutationhasoccurredandincomparable sporadictumors. constitutional deletion ofchromosome 15qll-13 which was
This type of analysis has been performed on a range of inherited from the father (155), whereas children with the
tumors and has disclosed a marked distortion in the very different Angelman syndrome may have the very
parental origin oftheinitiallymutated chromosome (Table samedeletionbutinheritedfromthemother(156). In some
3).Various mechanisms havebeenproposed to accountfor Prader-Willi patients in whom the deletion is not evident
Table 3. Parental origin ofmutated allele in tumors (individuals) in some inherited cancer predispositions.
Origin ofrelated/mutant
Tumor/syndrome/ allele in tumora
allele (chromosome) No. offamilies/cases Paternal Maternal References
Retinoblastoma 22 20 2 Ejima et al. (141-143)
Rb (13ql.4) (constitutional) Dryja etal. (142)
Zhu et al. (143)
Osteosarcoma 13 12 1 Toguchida et al. (144)
Rb (13q14) (sporadic)
Neurofibromatosisa 14 12 2 Jadayel et al. (145)
NF1 (17q11.2) (constitutional)
Wilms' tumor 18 16 2 Schroeder et al. (146-148),
WT (llpl3) (sporadic) Mannens et al. (147), Huff et
al. (148)
Rhabdomyosarcoma 6 6 0 Serable et al. (149)
(constitutional)
aParental origin ofmutation bypedigree linkage analysis and not tumorbiopsy.
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there is no paternal contribution ofrelevantloci and the pa-
tients are disomic for maternally derived chromosome 15s.
Genetic (mutations) or epigenetic (imprinting) inactiva-
tion ofatumor-suppressor geneisfunctionallyequivalent,
and it is obvious that imprinting may be an important
factor in carcinogenesis. Various hypotheses have been
proposed to account for the large excess of mutations
arising in suppressor genes in paternal germ cells in
inherited cancers and in somatic cells in sporadic cases,
and for the preferential loss ofmaternally inherited sup-
pressorloci. Manyoftheseincludeproposals thatimprint-
ing is associated with a high mutation rate (145), that
mutations may affect the genes that control imprinting
(149), and thatimprinted chromosomes (or segments) may
be more subject to loss. Relevant to these suggestions are
two recent reports. The first is by Sakai et al (157) on the
methylation pattern at the 5' end of the retinoblastoma
gene, including its promoter region and the first exon, in
the DNA from 56 primary retinoblastomas. It transpired
that both copies of the Rbl gene in four of these tumors
from patients with unilateral retinoblastoma were hyper-
methylated, whereas the gene in their blood cells was not.
No mutation was observed, implying an epigenetic origin
for the loss of tumor suppressing activity. The second
study was by Henry et al. (158) on the etiology of the
Beckwith-Weidemann syndrome, which is a fetal over-
growth syndrome thatarises sporadically, or as a result of
the inheritance of an autosomal dominant mutation linked
to lipl5.5, and is often associated with Wilms' tumor. A
substantialproportionofBWS cases, ofbothinheritedand
sporadicforms,have nowbeenshowntobeassociatedwith
paternal disomy/maternal nullisomy of the lipi5 region
(158). Evidence from studies in mice shows that the
insulin-like growth factor-2 gene, which is located at the
lipl5.5 region in the human genome, is imprinted and is
not expressed on the maternally derived chromosomes
(159,160). These findings lend support to the implication
that there may be a tumor suppressor gene at this site in
the human genome which is not expressed in maternally
derived chromosomes. It is also relevant to note that the
short arm of chromosome 11 is a hot spot for hyper-
methylation invarioushumanneoplasms (161), andthereis
direct evidence ofmethylation of a CpG island associated
with the WT1 gene in some Wilms' tumors (162).
Concluding Comments
The emergence of metastatic cancer undoubtedly
depends upon mutational or epigenetic changes in a num-
ber of genes. The orderinwhich these changes occur may
be less important than the number and types of changes
(163). The genes involved may act in a positive fashion as
oncogenes promotingproliferation orin anegativefashion
as suppressor genes whose function is to inhibit uncon-
trolled growth in some instances perhaps by promoting
cellular differentiation or apoptosis. There must therefore
be a wide variety of suppressor genes, and we are some
way from a clear understanding ofthe modes ofaction of
even the best known. Recent progress in this area has,
however, been quite dramatic.
Genetic and molecular studies on lower eukaryotes,
which have been extended to include mammalian cells
(164), have identified families of molecules, cyclins, that
undergo cell cycle associated fluctuations which reach
their maximal levels at the G2:M transition and are
destroyedduringmitosis. Somemembersofthefamiliesof
cyclins (B type) interact with p34cdc2, a kinase which is
activated in cells entering mitosis and shows maximal
activityatmetaphase.Others(G1 andAtypes), atleast one
ofwhich may act as an oncogene (165), may be involved in
the transition of cells into and through Gi, and in the
process oftriggering cells to enter the S phase (166,167).
The emerging understanding ofthese positive controls of
cellular proliferation has thrown light on the negative role
played by the wild-type Rb protein. As already indicated,
the non-phosphorylated form of Rb blocks the entry of
cellsinto S, ablockagethatisremovedbyphosphorylation.
Rb protein in these Gi cells has been found to be bound to
thetranscription factorE2F. This Rb/E2F complexdisap-
pears at the G1:S boundary following phosphorylation of
Rb and is replaced by an E2F/cyclin A complex. Negative
control of Rb would therefore appear to be exerted by
preventing interaction of the transcription factor with
cyclin promoters. Two groups have recently provided fur-
ther support for this role (168,169), by demonstrating that
mutant forms ofthe Rb protein are no longer able to bind
to E2F.
What of the roles of tumor-suppressor genes that act
dominantly in negating the effects of oncogenes or in
promoting cellular differentiation and apoptosis? Genes
such as the K-rev-1 ras-related gene have been shown to
have dominant suppressor activityagainst a specific set of
oncogenes (170), but no gene ofthis type has been associ-
ated with inherited cancer susceptibility. An increasing
number of differentiation pathways have been identified,
particularly in relation to the hematopoietic system, and a
number of important genes identified, but none has been
implicated in inherited cancer predispositions. A large
Table 4. Human genes that may have tumor-suppressor activity.
Gene Gene product and function
Rbl Nuclear phosphoprotein Modifier oftranscription factor that regulates mitotic cycle genes
p53 Nuclear phosphoprotein Like Rbl, may regulate mitotic cycle genes
WT1 DNAbinding zinc finger protein Transcription factor
DCC Sequence similar to outer cell surface glycoprotein Cell adhesion and cell-cell interaction
MCC G-protein activator? Signal transduction
Coiled-coil structural protein Cell structure
NF1 Cytoplasmic GAP-like protein Intracellular signal transduction
PTPG Transmembrane protein-tyrosine phosphatase y Dephosphorylation oftyrosine
K-rev 1 Inner cell surface associated G-protein Interferes in the interaction between ras and its effector
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numberofgenes areinvolved innormal growth and differ-
entiationbutitdoes notfollowthatallofthesewillpossess
the properties oftumor-suppressor genes. It maybe rele-
vant to note the increasing interest in the genes that are
responsibleforprogrammingcelldeathorinblockingsuch
programs, e.g., the bc12 oncogene (171), and the recent
report that wild-type p53 induces apoptosis in myeloid
leukemic cells which is inhibited by the cytokine inter-
leukin-6, which itself promotes monocyte differentiation
(172).
Finally, it is evident that the term "tumor-suppressor
genes" is applicable to awide variety ofgenes involved in
normal cellular functioning. The unifying characteristic
appears tobethenecessityofhavingonefunctioningwild-
type allele in order to prevent abnormal proliferation or
differentiation atparticular stagesofcellgrowth. Itisthis
feature thatpermits normal activityin ahemizygous state
and underlies the association ofsome ofthese genes with
certaininherited cancerpredispositions. Todatethegenes
identified within this category are of diverse function
(Table4). Somemayactwithin anarrowrangeofcelltypes
and consequently be involved in the etiology of relatively
few tumor types, as with WT1. Others, of fundamental
importance to the growth and maintenance of a broad
range of cells, will be found to be implicated in many
tumors as with p53 and Rbl. Since many of these genes
appear to act as negative regulators ofcellular prolifera-
tion, andtheirpresenceinasingle copyissufficientforthe
normal control of proliferation, they may well offer an
important approach for the future therapeutic control of
abnormal growth.
This manuscript was presented at the Conference on Biomonitoring
and Susceptibility Markers in Human Cancer: Applications in Molecular
Epidemiology and Risk Assessment that was held in Kailua-Kona,
Hawaii, 26October-i November 1991.
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